secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2026-07-20T20:27:24+00:00
Accession:  0001683168-26-005656
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma enters $4M ATM equity facility with Aegis Capital
--------------------------------------------------------------------

- Up to $4M of common stock may be sold at-the-market through Aegis Capital as exclusive agent.
- Aegis receives 3.0% commission on gross proceeds plus expense reimbursement.
- Shares issued under existing S-3 shelf (File No. 333-284142) effective Jan 15, 2025.
- No obligation to sell; Company controls timing and volume via placement notices.
- Agreement can be terminated by either party per its terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826005656/0001683168-26-005656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826005656/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-005656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer